Format

Send to

Choose Destination
J Am Coll Cardiol. 2018 May 8;71(18):2058-2072. doi: 10.1016/j.jacc.2018.03.459.

Valvular Heart Disease in Patients ≥80 Years of Age.

Author information

1
Columbia University Medical Center/New York Presbyterian Hospital, New York, New York. Electronic address: skodali@columbia.edu.
2
Columbia University Medical Center/New York Presbyterian Hospital, New York, New York.
3
Brown University, Providence, Rhode Island.

Abstract

In the United States, the octogenarian population is projected to triple by 2050. With this aging population, the prevalence of valvular heart disease (VHD) is on the rise. The etiology, approach to treatment, and expected outcomes of VHD are different in the elderly compared with younger patients. Both stenotic and regurgitant lesions are associated with unfavorable outcomes if left untreated. Surgical mortality remains high due to multiple co-morbidities, and long-term survival benefit is dependent on many variables including valvular pathology. Quality of life is an important consideration in treatment decisions in this age group. Increasingly, octogenarian patients are receiving transcatheter therapies, with transcatheter aortic valve replacement having the greatest momentum. Numerous transcatheter devices for management of other valve lesions are currently in early clinical trials. This review will describe the epidemiology, etiology, diagnosis, and therapeutic options for VHD in the oldest old, with a focus on transcatheter technologies.

KEYWORDS:

elderly; regurgitation; stenosis; transcatheter technology; valvular heart disease

PMID:
29724358
DOI:
10.1016/j.jacc.2018.03.459

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center